Первая клетка. И чего стоит борьба с раком до последнего - Азра Раза
Шрифт:
Интервал:
Закладка:
Sansregret L., Swanton Ch. The Role of Aneuploidy in Cancer Evolution. Cold Spring Harbor Perspectives in Medicine. October 21, 2016. doi:10.1101/cshperspect.a028373.
Rous P. A Sarcoma of the Fowl Transmissible by an Agent Separable from the Tumor Cells. Journal of Experimental Medicine. 13, no. 4 (1911): 397–399.
Rous P. The Challenge to Man of the Neoplastic Cell. Nobel lecture, December 13, 1966. www.nobelprize.org/prizes/medicine/1966/rous/lecture
Kumar P., Murphy F. A. Francis Peyton Rous. Emerging Infectious Diseases. 19, no. 4 (2013): 660–663.
Rubin H. The Early History of Tumor Virology: Rous, RIF, and RAV. PNAS. 108 (2011): 14389–14396.
Weiss R. A., Vogt P. K. 100 Years of Rous Sarcoma Virus. Journal of Experimental Medicine. 208 (2011): 2351–2355.
Burkitt D. A Sarcoma Involving the Jaws in African Children. British Journal of Surgery. 46, no. 197 (1958): 218–223.
Smith E. 50 Years of Epstein-Barr Virus. Cancer Research UK. https://scienceblog.cancerresearchuk.org/2014/03/26/50-years-of-epstein-barr-virus/
Javier R. T., Butel J. S. The History of Tumor Virology. Cancer Research. 68, no. 19 (2008): 7693–7706.
Bister K. Discovery of Oncogenes: The Advent of Molecular Cancer Research. PNAS. 112, no. 50 (2015): 15259–15260.
Lane D., Levine A. P53 Research: The Past 30 Years and the Next 30 Years. Cold Spring Harbor Perspectives in Biology. 2, no. 12 (2010): a000893.
Donehower L. A. Using Mice to Examine p53 Functions in Cancer, Aging, and Longevity. Cold Spring Harbor Perspectives in Biology. 1, no. 6 (2009): a001081.
Lane D. P. et al. P53-Based Cancer Therapy. Cold Spring Harbor Perspectives in Biology. 2, no. 9 (2010): a001222.
Bieging K. T. et al. Unravelling Mechanisms of p53-Mediated Tumour Suppression. Nature Reviews Cancer. 14 (2014): 359–370.
Li F. P., Fraumeni J. F. Soft-Tissue Sarcomas, Breast Cancer, and Other Neoplasms: A Familial Syndrome? Annals of Internal Medicine. 71, no. 4 (1969): 747–752.
Hisada M. et al. Multiple Primary Cancers in Families with Li-Fraumeni Syndrome. Journal of the National Cancer Institute. 90, no. 8 (1998): 606–611.
Birch J. M. et al. Prevalence and Diversity of Constitutional Mutations in the p53 Gene Among 21 Li-Fraumeni Families. Cancer Research. 54, no. 5 (1994): 1298–1304.
Greicius J. And Yet, You Try: A Father’s Quest to Save His Son. Stanford Medicine: Diagnostics, Fall 2016. https://stanmed.stanford.edu/2016fall/milan-gambhirs-li-fraumeni-syndrome.html
Haase D. TP53 Mutation Status Divides Myelodysplastic Syndromes with Complex Karyotypes into Distinct Prognostic Subgroups. Nature, January 2019. doi:10.1038/s41375-018-0351-2.
Martinez-Hoyer S. et al. Mechanisms of Resistance to Lenalidomide in Del(5q) Myelodysplastic Syndrome Patients. Blood. 126 (2015): 5228.
Abegglen L. M. et al. Potential Mechanisms for Cancer Resistance in Elephants and Comparative Cellular Response to DNA Damage in Humans. JAMA. 314, no. 17 (2015): 1850–1860.
Caulin A. F., Maley C. C. Peto’s Paradox: Evolution’s Prescription for Cancer Prevention. Trends in Ecology & Evolution. 26, no. 4 (2011): 175–182.
Tollis M. et al. Paradox: How Has Evolution Solved the Problem of Cancer Prevention? BMC Biology. 15, no. 60 (2017).
Callaway E. How Elephants Avoid Cancer: Pachyderms Have Extra Copies of a Key Tumour-Fighting Gene. Nature, October 8, 2015. doi:10.1038/nature.2015.18534.
Armstrong S. P53: The Gene That Cracked the Cancer Code. New York: Bloomsbury Sigma, 2016.
GarcÍa-Cao I. “Super p53” Mice Exhibit Enhanced DNA Damage Response, Are Tumor Resistant and Age Normally. EMBO Journal. 21, no. 22 (2002): 6225–6235.
Hogenboom M. The Animal That Don’t Get Cancer. BBC, October 31, 2015. www.bbc.com/earth/story/20151031-the-animal-that-doesnt-get-cancer
Tomasetti C. et al. Stem Cell Divisions, Somatic Mutations, Cancer Etiology, and Cancer Prevention. Science. 355, no. 331 (2017): 1330–1334.
Vogelstein B. et al. Cancer Genome Landscapes. Science. 339, no. 6127 (2013): 1546–1558.
New Study Finds That Most Cancer Mutations Are Due to Random DNA Copying ‘Mistakes’. Johns Hopkins Medicine, March 23, 2017. www.hopkinsmedicine.org/news/media/releases/new_study_finds_that_most_cancer_mutations_are_due_to_random_dna_copying_mistakes
Yachida S. et al. Distant Metastasis Occurs Late During the Genetic Evolution of Pancreatic Cancer. Nature. 467 (2010): 1114–1117.
Pienta K. et al. The Cancer Diaspora: Metastasis Beyond the Seed and Soil Hypothesis. Clinical Cancer Research. 19, no. 21 (2013). doi:10.1158/1078–0432. CCR-13–2158.
McGranahan N., Swanton Ch. Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future. Cell. 168 (2017): 631.
Giam M., Rancati G. Aneuploidy and Chromosomal Instability in Cancer: A Jackpot to Chaos. Cell Division. 10 (2015): 3.
How Well Do We Understand the Relation Between Incorrect Chromosome Number and Cancer? EurekAlert! www.eurekalert.org/pub_releases/2017–01/cshl-hwd011117.php
Sheltzer J. M. et al. Single-Chromosome Gains Commonly Function as Tumor Suppressors. Cancer Cell. 31, no. 2 (2017): 240–255.
Ansari D. Pancreatic Cancer and Thromboembolic Disease, 150 Years After Trousseau. Hepatobiliary Surgery and Nutrition. 4, no. 5 (2015): 325–335.
Campisi J. Aging, Cellular Senescence, and Cancer. Annual Review of Physiology. 75 (2013): 685–705.
Lee S., Lee J-S. Cellular Senescence: A Promising Strategy for Cancer Therapy. BMB Reports. 52, no. 1 (2019): 35–41.
Lan W., Miao Y. Autophagy and Senescence. Senescence Signalling and Control in Plants. (2019): 239–253.
Franceschi C., Campisi J. Chronic Inflammation (Inflammaging) and Its Potential Contribution to Age-Associated Diseases. Journals of Gerontology: Series A. 69, supplement 1 (2014): S4–S9.
Harley C. B., Villeponteau B. Telomeres and Telomerase in Aging and Cancer. Current Opinion in Genetics & Development. 5, no. 2 (1995): 249–255.
Blackburn E., Epel E. The Telomere Effect: A Revolutionary Approach to Living Younger, Healthier, Longer. New York: Grand Central Publishing, 2017.
Steensma D. et al. Clonal Hematopoiesis of Indeterminate Potential and Its Distinction from Myelodysplastic Syndromes. Blood. 126 (2015): 9–16.
Jaiswal S. et al. Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes. New England Journal of Medicine. 371 (2014): 2488–2498.
Bertamini L. et al. Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Patients with Coronary Artery Disease and in Centenarians: Further Clues Linking CHIP with Cardiovascular Risk. Blood. 130 (2017): 1144.
Thomas H. Mutation and Clonal Selection in the Ageing Oesophagus. Nature Reviews Gastroenterology & Hepatology. 16 (2019): 139.
Martincorena I. et al. Somatic Mutant Clones Colonize the Human Esophagus with Age. Science. 362 (2018): 911–917.
Yokoyama A. et al. Age-Related Remodelling of Oesophageal Epithelia by Mutated Cancer Drivers. Nature. 565 (2019): 312–317.
Malcovati L. et al. Clinical Significance of Somatic Mutation in Unexplained Blood Cytopenia. Blood. 129 (2017): 3371–3378.
Fialkow P. J. et al. Evidence for a Multistep Pathogenesis of Chronic Myelogenous Leukemia. Blood. 58 (1981): 158–163.
Gilliland G. D. Nonrandom X–Inactivation Patterns in Normal Females: Lyonization Ratios Vary with Age. Blood. 88, no. 1 (1996): 59–65.
Raza A. Consilence Across Evolving Dysplasias Affecting Myeloid, Cervical, Esophageal, Gastric and Liver Cells: Common Themes and Emerging Patterns. Leukemia Research. 24, no. 1 (2000): 63–72.
Глава 3. Леди НMontoro J. et al. Improving Treatment for Myelodysplastic Syndromes Patients. Current Treatment Options in Oncology. 19 (2018): 66.
Fuchs Ota, ed. Recent Developments in Myelodysplastic Syndromes. London: IntechOpen, 2019.
Platzbecker U. Treatment of MDS. Blood. 133, no. 10 (2019): 1096–1107.
Ferrara F., Vitagliano O. Induction Therapy in Acute Myeloid Leukemia: Is It Time to Put Aside Standard 3 + 7? Hematological Oncology. (2019). doi:10.1002/hon.2615.
Cerrano M., Itzykson R. New Treatment Options for Acute Myeloid Leukemia in 2019. Current Oncology Reports. 21, no. 2 (2019): 16.
Buccisano F. The Emerging Role of Measurable Residual Disease Detection in AML in Morphologic Remission. Seminars in Hematology. 56, no. 2 (2019): 125–130.
Almeida A. et al. Recent Advances in the Treatment of Lower-Risk Non-Del(5q) Myelodysplastic Syndromes (MDS). Leukemia Research. 52 (2017): 50–57.
Luspatercept – Acceleron Pharma/Celgene Corporation. Adis Insight.
https://adisinsight.springer.com/drugs/800029519
Fenaux P. Luspatercept for the Treatment of Anemia in Myelodysplastic Syndromes and Primary Myelofibrosis. Blood. 133, no. 8 (2019): 790–794.
Prasad V. Do Cancer Drugs Improve Survival or Quality of Life? BMJ. 359 (2017): j4528.
Prasad V. et al. The High Price of Anticancer Drugs: Origins, Implications, Barriers, Solutions. Nature Reviews Clinical Oncology. 14 (2017): 381–390.
Keshavan M. Did He Really Just Tweet
